Boston-based 908 Devices and Minneapolis-based Bio-Techne Corp. announced a collaboration to develop an extended workflow solution for protein characterization.

Santa Fe-based Avisa Diagnostics Inc., formerly Fogchain Corp., said it has closed its reverse takeover transaction with Avisa Pharma Inc., of Santa Fe. The transaction was effected via a triangular merger of Avisa Diagnostics, Avisa Pharma and a wholly owned, Delaware subsidiary of the company, Subco. As a result of the transaction, the company issued to Avisa Pharma securityholders 35,891,962 common shares, 15,208,674 restricted shares, 2,127,396 options to purchase common shares and 7,034,964 common share purchase warrants, in exchange for the issued and outstanding securities of Avisa Pharma prior to completion of the deal. In conjunction with the merger, Avisa Pharma raised gross proceeds of $693,336.06 in private placement financing of subscription receipts.

Flurotest Ltd., of Calgary, reported that its high-throughput COVID-19 testing platform detected SARS-CoV-2 variants of concern.

Charlotte, N.C.-based Premier Inc. awarded a patient safety solution agreement to Ivwatch LLC of Newport News, Va.

Moleculight Corp., of Pittsburgh, received an innovative technology contract from Irving, Texas-based Vizient Inc. for its i:X Fluorescence Wound Imaging Device.

Milan-based Sentinel Diagnostics CH SpA launched two serological tests to assess the immune response to SARS-CoV-2 by testing total antibodies in human serum.

Minneapolis-based Smiths Medical partnered with Ivenix Inc., of Boston, to offer comprehensive infusion management solutions in the U.S.